# MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

> **NCT00618917** · PHASE1,PHASE2 · TERMINATED · sponsor: **Joel Greenberger** · enrollment: 18 (actual)

## Conditions studied

- Esophageal
- Toxicity

## Interventions

- **GENETIC:** Manganese Superoxide Dismutase Plasmid Liposome
- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00618917
- **Lead sponsor:** Joel Greenberger
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11-11
- **Primary completion:** 2010-02-26
- **Final completion:** 2011-08-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** MnSOD longer available during Phase II
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00618917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00618917, "MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00618917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*